Name: Medium-chain Triglycerides
CAS No: Medium-chain triglycerides [73398-61-5]
BP: Medium-chain Triglycerides PhEur: Triglycerides, Medium-Chain USP-NF: Medium-Chain Triglycerides
Bergabest; caprylic/capric triglyceride; Captex 300; Captex 355; Crodamol GTCC-PN; glyceryl tricaprylate/caprate; Labrafac CC; Labrafac Lipo; MCT oil; Miglyol 810; Miglyol 812; Myritol; Neobee M5; Nesatol; oleum neutrale; oleum vegetable tenue; thin vegetable oil; triglycerida saturata media; Waglinol 3/9280.
Medium-chain triglycerides [73398-61-5]
500 (average) 500 (average) The PhEur 6.0 describes medium-chain triglycerides as the fixed oil extracted from the hard, dried fraction of the endosperm of Cocos nucifera L. or from the dried endosperm of Elaeis guineenis Jacq. They consist of a mixture of triglycerides of saturated fatty acids, mainly of caprylic acid and of capric acid. They contain not less than 95% of saturated fatty acids.
Medium-chain triglycerides have been used in a variety of pharmaceutical formulations including oral, parenteral, and topical preparations. In oral formulations, medium-chain triglycerides are used as the base for the preparation of oral emulsions, microemulsions, selfemulsifying systems, solutions, or suspensions of drugs that are unstable or insoluble in aqueous media, e.g. calciferol. Mediumchain triglycerides have also been investigated as intestinalabsorption enhancers(1,2) and have additionally been used as a filler in capsules and sugar-coated tablets, and as a lubricant or antiadhesion agent in tablets. In parenteral formulations, medium-chain triglycerides have similarly been used in the production of emulsions, solutions, or suspensions intended for intravenous administration.(3–9) In rectal formulations, medium-chain triglycerides have been used in the preparation of suppositories containing labile materials. In cosmetics and topical pharmaceutical preparations, medium-chain triglycerides are used as a component of ointments, creams, and liquid emulsions.(5) Therapeutically, medium-chain triglycerides have been used as nutritional agents.(10) Diets containing medium-chain triglycerides are used in conditions associated with the malabsorption of fat, such as cystic fibrosis, since medium-chain triglycerides are more readily digested than long-chain triglycerides. Medium-chain triglycerides have been particularly investigated for their use in total parenteral nutrition (TPN) regimens in combination with longchain triglycerides.(4,11) Although similar to long-chain triglycerides, medium-chain triglycerides have a number of advantages in pharmaceutical formulations, which include better spreading properties on the skin; no impedance of skin respiration; good penetration properties; good emollient and cosmetic properties; no visible film on the skin surface; good compatibility; good solvent properties; and good stability against oxidation.
A colorless to slightly yellowish oily liquid that is practically odorless and tasteless. It solidifies at about 08C. The oil is free from catalytic residues or the products of cracking
See Table I.
Acid value 40.1 for Crodamol GTC/C; 40.1 for Miglyol 810; 40.1 for Miglyol 812; 40.05 for Neobee M5. Cloud point 458C for Crodamol GTC/C; 108C for Miglyol 810; 108C for Miglyol 812. Color 460 (Hazen color index) for Crodamol GTC/C; 490 (Hazen color index) for Miglyol 810; 460 (Hazen color index) for Miglyol 812; 4100 (Hazen color index) for Neobee M5. Density 0.94–0.96 g/cm3 for Crodamol GTC/C at 208C; 0.94–0.95 g/cm3 for Miglyol 810 at 208C; 0.94–0.95 g/cm3 for Miglyol 812 at 208C; 0.94 g/cm3 for Neobee M5 at 208C. Freezing point 58C for Neobee M5 Hydroxyl value 48 for Neobee M5 Iodine number 41.0 for Crodamol GTC/C; 40.5 for Miglyol 810; 40.5 for Miglyol 812; 40.5 for Neobee M5. Moisture content 40.15% w/w for Crodamol GTC/C; 40.10% w/w for Miglyol 810; 40.10% w/w for Miglyol 812; 40.15% w/w for Neobee M5. Peroxide value 41.0 for Miglyol 810; 41.0 for Miglyol 812; 40.5 for Neobee M5. Refractive index 1.4485–1.4500 for Crodamol GTC/C at 208C; 1.4485–1.4505 for Miglyol 810 at 208C; 1.4490–1.4510 for Miglyol 812 at 208C; 1.4480–1.4510 for Neobee M5 at 208C. Saponification value 325–345 for Crodamol GTC/C; 335–355 for Miglyol 810; 325–345 for Miglyol 812; 335–360 for Neobee M5. Solubility Soluble in all proportions at 208C in acetone, benzene, 2-butanone, carbon tetrachloride, chloroform, dichloromethane, ethanol, ethanol (95%), ether, ethyl acetate, petroleum ether, special petroleum spirit (boiling range 80–1108C), propan2-ol, toluene, and xylene. Miscible with long-chain hydrocarbons and triglycerides; practically insoluble in water. Surface tension 32.2 mN/m for Crodamol GTC/C at 258C; 31.0 mN/m for Miglyol 810 at 208C; 31.1 mN/m for Miglyol 812 at 208C; 32.3 mN/m for Neobee M5 at 258C. Viscosity (dynamic) 27–30 mPa s (27–30 cP) for Miglyol 810 at 208C; 28–32 mPa s (28–32 cP) for Miglyol 812 at 208C; 23 mPa s (23 cP) for Neobee M5 at 258C.
Medium-chain triglycerides are stable over the wide range of storage temperatures that can be experienced in tropical and temperate climates. Ideally, however, they should be stored at temperatures not exceeding 258C and not exposed to temperatures above 408C for long periods. At low temperatures, samples of medium-chain triglycerides may become viscous or solidify. Samples should therefore be well melted and mixed before use, although overheating should be avoided. In the preparation of microemulsions and self-emulsifying systems, emulsions, or aqueous suspensions of medium-chain triglycerides, care should be taken to avoid microbiological contamination of the preparation, since lipase-producing microorganisms, which become active in the presence of moisture, can cause hydrolysis of the triglycerides. Hydrolysis of the triglycerides is revealed by the characteristic unpleasant odor of free mediumchain fatty acids. Medium-chain triglycerides may be sterilized by maintaining at 1708C for 1 hour. Medium-chain triglycerides should be stored protected from light in a well-filled and well-closed container. When stored dry, in sealed containers, medium-chain triglycerides remain stable for many years.
Preparations containing medium-chain triglycerides should not come into contact with polystyrene containers or packaging components since the plastic rapidly becomes brittle upon contact. Low-density polyethylene should also not be used as a packaging material as the medium-chain triglycerides readily penetrate the plastic, especially at high temperatures, forming an oily film on the outside. High-density polyethylene is a suitable packaging material. Closures based on phenol resins should be tested before use for compatibility with medium-chain triglycerides. Polyvinyl chloride packaging should also be tested for compatibility since mediumchain triglycerides can dissolve some plasticizers, such as phthalates, out of the plastic. Materials recommended as safe for packaging medium-chain triglycerides are low-density polyethylene, polypropylene, glass, and metal
Medium-chain triglycerides are obtained from the fixed oil extracted from the hard, dried fraction of the endosperm of Cocos nucifera L. Hydrolysis of the fixed oil followed by distillation yields the required fatty acids, which are then re-esterified to produce the medium-chain triglycerides. Although the PhEur 6.0 specifies that medium-chain fatty acids are obtained from coconut oil, medium-chain triglycerides are also to be found in substantial amounts in the kernel oils of certain other types of palm-tree, e.g. palm kernel oil and babassu oil. Some animal products, such as milk-fat, also contain small amounts (up to 4%) of the medium-chain fatty acid esters.
Medium-chain triglycerides are used in a variety of pharmaceutical formulations including oral, parenteral, and topical products, and are generally regarded as essentially nontoxic and nonirritant materials. In acute toxicology studies in animals and humans, no irritant or other adverse reactions have been observed; for example, when they were patch-tested on more than 100 individuals, no irritation was produced on either healthy or eczematous skin. Medium-chain triglycerides are not irritating to the eyes. Similarly, chronic toxicology studies in animals have shown no harmful adverse effects associated with medium-chain triglycerides following inhalation or intraperitoneal, oral, and parenteral administration. In humans, administration of 0.5 g/kg body-weight mediumchain triglycerides to healthy individuals produced no change in blood or serum triglycerides compared to subjects receiving the same dose of the long-chain triglyceride triolein. In patients consuming diets based on medium-chain triglycerides, adverse effects reported include abdominal pain and diarrhea. LD50 (mouse, IV): 3.7 g/kg LD50 (mouse, oral): 29.6 g/kg LD50 (rat, oral): 33.3 g/kg
Observe normal precautions appropriate to the circumstances and quantity of material handled.
GRAS listed. Included in the FDA Inactive Ingredients Database (topical preparations). Included in nonparenteral and parenteral medicines licensed in Europe. Included in the Canadian List of Acceptable Non-medicinal Ingredients.
Coconut oil; suppository bases, hard fat; vegetable oil, hydrogenated.
Medium-chain glycerides may also be known as fractionated coconut oil, which contains three saturated lipid chains bound to a glycerin backbone, and are distinguished from other triglycerides by the length of the carbon chains, normally between 6 and 10.